Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEORAF study
2021-000828-35Phase 2Active
- Sponsor
- Fédération Francophone de Cancérologie Digestive
- Start
- Jan 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of encorafenib and cetuximab in colon adenocarcinoma and rectal adenocarcinoma, sponsored by Fédération Francophone de Cancérologie Digestive. Primary endpoint: Tumor regression rate. Started Jan 2022; status: active.
02
Drugs
encorafenibcetuximab
03
Conditions
colon adenocarcinomarectal adenocarcinoma
Beyond the preview
Go deeper on 2021-000828-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000828-35.